00771VAB4
Aerie Pharmaceuticals Inc
Could not find a ticker for this position, may be a filing error
A maker of prescription eye drops for glaucoma and high eye pressure, best known for its once-daily drops Rhopressa and Rocklatan, used by people living with these sight-threatening conditions. It was founded in 2005 by a Duke University eye surgeon and colleagues who aimed to target the root cause of the disease rather than just its symptoms. The name is a play on "eyrie," the lofty nest of a bird of prey, fitting for a company all about vision; in 2022 it was folded into the global eye-care giant Alcon.
CONVERTIBLEUnderlying: AERICUSIP: 00771VAB4HealthcareUS1 derivative reporter
1.50% Convertible Senior Notes due October 1, 2024
No tracked superinvestor held this security as stock in this period — only the derivative positions below reference it.
Derivative Reporters
Investor
Kind
13F reported value
Quantity
Change
